Novo Nordisk's weight-loss challenge in five charts

Core Insights - Novo Nordisk has received U.S. regulatory approval for its weight-loss pill, which may help the company recover from significant market capital loss and competition from Eli Lilly [1][2] - The approval comes after a challenging year for Novo, characterized by declining share prices, profit warnings, and slowing sales of its flagship product, Wegovy [2] Company Performance - Novo Nordisk's market capitalization has decreased from $650 billion in June last year to over $240 billion currently, indicating a loss of more than half its value [6] - The company's share price has significantly declined compared to its rivals over the past year [3] Competitive Landscape - Eli Lilly's Zepbound has surpassed Wegovy in U.S. prescriptions this year, marking a shift in the competitive dynamics of the obesity treatment market [2] - Novo was the first to market with Wegovy, approved in 2021, but has faced intensified competition since the launch of Zepbound in late 2023 [2] Financial Metrics - Novo's price-earnings ratio has returned to levels more in line with its peers, having previously commanded a significant premium [4] - The company has incurred rising costs due to investments in expanding manufacturing and sales capacity [5]